Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

KRAS-AlphaTACs: a novel class of biotherapeutics to target KRAS

Project description

Selective KRAS degradation

KRAS is a key oncogene with mutations encountered very frequently in different types of cancer. Even in the absence of mutations, KRAS signalling is frequently activated, making it a major therapeutic target. Efforts to inhibit KRAS have intensified, particularly with the approval of KRAS-G12C inhibitors. The ERC-funded RAS-AlphaTAC project proposes to target KRAS by activating its degradation. The work is based on proteolysis-targeted chimeric (PROTAC) molecules which specifically degrade proteins through the ubiquitin proteasomal machinery. In this project, researchers will develop a new therapeutic modality (AlphaTAC) that combines a PROTAC molecule and a non-immunoglobulin antibody scaffold capable of penetrating cancer cells. This selective therapeutic approach can serve as a proprietary platform for different targets and types of cancer.

Objective

The RAS pathway is the most frequently activated signaling node in human cancer. Activating KRAS mutations are found in approximately one in seven human cancers. KRAS signaling is also activated in a significant subset of human cancers that lack KRAS mutations. Targeting KRAS has been a central goal during the past four decades, and the efforts have intensified over the past years, ignited by the approval of the KRAS-G12C inhibitors. A targeted KRAS degradation approach is an attractive solution for blocking KRAS activity, and within the Ub-RASDisease project, we explored the degradability of wild-type and mutant KRAS proteins. In parallel, my group initiated studies to combine the Alphabody technology with the targeted protein degradation approach by designing an AlphaTAC as a novel therapeutic modality. The goal of this project is to generate and pre-clinically validate AlphaTACs targeting KRAS for degradation. This will strengthen the Proof of concept on the AlphaTAC utility in targeted protein degradation and provide support for establishing a proprietary platform in view of the creation of a new spin-off company.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2023-POC

See all projects funded under this call

Host institution

VIB VZW
Net EU contribution
€ 150 000,00
Address
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgium
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)